{"id":1834,"date":"2026-11-17T15:06:52","date_gmt":"2026-11-17T15:06:52","guid":{"rendered":"http:\/\/afire-gene.com\/gout-methylation-study\/"},"modified":"2026-11-17T15:06:52","modified_gmt":"2026-11-17T15:06:52","slug":"gout-methylation-study","status":"publish","type":"page","link":"https:\/\/afire-gene.com\/en\/gout-methylation-study\/","title":{"rendered":"Gout DNA Methylation Study"},"content":{"rendered":"<div class=\"gout-article\">\n<div class=\"gout-zh\">\n<p class=\"gout-kicker\">\u7532\u57fa\u5316\u6d4b\u5e8f \u00b7 \u8868\u89c2\u57fa\u56e0\u7ec4\u5b66\u670d\u52a1 \u00b7 \u6210\u679c\u89e3\u8bfb\u4e13\u520a<\/p>\n<h2 class=\"gout-h1\">\u8fc4\u4eca\u56fd\u5185\u89c4\u6a21\u6700\u5927\u7684\u75db\u98ce DNA \u7532\u57fa\u5316\u7814\u7a76<\/h2>\n<p class=\"gout-sub\">\u53d1\u8868\u4e8e\u98ce\u6e7f\u75c5\u5b66\u9876\u520a <strong>Ann Rheum Dis<\/strong>\uff082026\uff09\u00b7 IF 24 \u00b7 \u4e2d\u79d1\u9662\u4e00\u533a<\/p>\n\n<div class=\"gout-stats\">\n  <div class=\"gout-stat\"><span class=\"gout-num\">369<\/span><span class=\"gout-label\">\u7532\u57fa\u5316\u6d4b\u5e8f\u961f\u5217\u6837\u672c<\/span><\/div>\n  <div class=\"gout-stat\"><span class=\"gout-num\">0.96<\/span><span class=\"gout-label\">\u7532\u57fa\u5316\u8bca\u65ad\u6a21\u578b\u6700\u9ad8 AUC<\/span><\/div>\n  <div class=\"gout-stat\"><span class=\"gout-num\">84<\/span><span class=\"gout-label\">\u9057\u4f20-\u8868\u89c2\u4ea4\u6c47\u57fa\u56e0<\/span><\/div>\n<\/div>\n\n<h3>\u6838\u5fc3\u901f\u89c8<\/h3>\n<table class=\"gout-table\">\n<tbody>\n<tr><th>\u53d1\u8868\u671f\u520a<\/th><th>\u7532\u57fa\u5316\u6d4b\u5e8f\u961f\u5217<\/th><th>\u8bca\u65ad\u6a21\u578b\u6700\u9ad8 AUC<\/th><\/tr>\n<tr><td>IF 24 \u00b7 \u4e2d\u79d1\u9662\u4e00\u533a<br>Ann Rheum Dis\uff08\u98ce\u6e7f\u75c5\u5b66\u9876\u520a\uff09<\/td><td>369 \u4f8b<br>\u75db\u98ce 124 \/ \u9ad8\u5c3f\u9178 121 \/ \u5bf9\u7167 124<\/td><td>0.96<br>\u75db\u98ce vs \u6b63\u5e38\u5bf9\u7167\uff08\u4ec5\u7532\u57fa\u5316\uff09<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<p>\u8fd1\u65e5\uff0c\u75db\u98ce\u8868\u89c2\u57fa\u56e0\u7ec4\u5b66\u9886\u57df\u8fce\u6765\u4e00\u9879\u91cc\u7a0b\u7891\u7814\u7a76\u2014\u2014\u6b63\u5f0f\u53d1\u8868\u4e8e\u98ce\u6e7f\u75c5\u5b66\u9876\u7ea7\u671f\u520a\u300aAnnals of the Rheumatic Diseases\u300b\uff08Ann Rheum Dis\uff0c\u5f71\u54cd\u56e0\u5b50 24\uff0c\u4e2d\u79d1\u9662\u4e00\u533a\uff09\u3002\u8be5\u7814\u7a76\u7531\u9752\u5c9b\u5927\u5b66\u9644\u5c5e\u533b\u9662\u3001\u590d\u65e6\u5927\u5b66\u9644\u5c5e\u534e\u5c71\u533b\u9662\u3001\u534e\u5357\u7406\u5de5\u5927\u5b66\u4e0e\u725b\u6d25\u5927\u5b66\u80af\u5c3c\u8fea\u98ce\u6e7f\u75c5\u7814\u7a76\u6240\u7b49\u56e2\u961f\u8054\u5408\u5b8c\u6210\uff0c\u6211\u53f8\u627f\u62c5\u4e86\u5168\u6d41\u7a0b DNA \u7532\u57fa\u5316\u6d4b\u5e8f\u4e0e\u8868\u89c2\u57fa\u56e0\u7ec4\u5b66\u5206\u6790\u670d\u52a1\u3002<\/p>\n<p>\u7814\u7a76\u4ee5 369 \u4f8b\u53d7\u8bd5\u8005\u6784\u5efa\u4e86\u76ee\u524d\u516c\u5f00\u62a5\u9053\u4e2d\u89c4\u6a21\u6700\u5927\u7684\u75db\u98ce \/ \u9ad8\u5c3f\u9178\u8840\u75c7 DNA \u7532\u57fa\u5316\u961f\u5217\uff0c\u5e76\u9996\u6b21\u5efa\u7acb\u5e76\u9a8c\u8bc1\u4e86\u6027\u80fd\u7a81\u51fa\u7684\u7532\u57fa\u5316\u8bca\u65ad\u6a21\u578b\uff1a\u75db\u98ce vs \u6b63\u5e38\u5bf9\u7167 AUC \u9ad8\u8fbe 0.96\uff0c\u4e34\u5e8a\u6700\u96be\u533a\u5206\u7684\u75db\u98ce vs \u65e0\u75c7\u72b6\u9ad8\u5c3f\u9178\u8840\u75c7\u5219\u4ece 0.67 \u63d0\u5347\u81f3 0.87\u3002\u8fd9\u4e0d\u4ec5\u662f\u4e00\u6b21\u65b9\u6cd5\u5b66\u7a81\u7834\uff0c\u66f4\u610f\u5473\u7740\uff1a&#8221;\u5c3f\u9178\u9ad8&#8221;\u548c&#8221;\u5f97\u4e86\u75db\u98ce&#8221;\u4e4b\u95f4\u90a3\u9053\u672a\u88ab\u89e3\u5f00\u7684\u9e3f\u6c9f\uff0c\u7b2c\u4e00\u6b21\u88ab\u7532\u57fa\u5316\u5c42\u5199\u4e0b\u4e86\u5206\u5b50\u6ce8\u89e3\u3002<\/p>\n\n<h3>\u4e00\u3001\u7814\u7a76\u80cc\u666f\uff1a\u4e3a\u4ec0\u4e48&#8221;\u5c3f\u9178\u9ad8&#8221;\u4e0d\u7b49\u4e8e&#8221;\u75db\u98ce&#8221;<\/h3>\n<p>\u75db\u98ce\u6e90\u4e8e\u957f\u671f\u9ad8\u5c3f\u9178\u8840\u75c7\u4e0b\u5c3f\u9178\u76d0\u6676\u4f53\u6c89\u79ef\uff0c\u4f46\u8840\u5c3f\u9178\u5347\u9ad8\u53ea\u662f\u5fc5\u8981\u6761\u4ef6\u2014\u2014\u7edd\u5927\u591a\u6570\u9ad8\u5c3f\u9178\u4eba\u7fa4\u7ec8\u8eab\u4e0d\u4f1a\u53d1\u75c5\u3002\u65e2\u5f80 GWAS \u627e\u5230\u7684\u6613\u611f\u53d8\u5f02\u591a\u4f4d\u4e8e\u975e\u7f16\u7801\u533a\uff0c\u53ea\u80fd\u89e3\u91ca\u5f88\u5c0f\u4e00\u90e8\u5206\u98ce\u9669\u3002DNA \u7532\u57fa\u5316\u6b63\u662f\u8fde\u63a5\u9057\u4f20\u80cc\u666f\u4e0e\u73af\u5883\u66b4\u9732\u7684\u5173\u952e\u8868\u89c2\u5f00\u5173\uff1b\u800c\u6b64\u524d\u7814\u7a76\u4ec5\u505c\u7559\u5728\u4e2a\u522b\u5019\u9009\u57fa\u56e0\uff0c\u4ece\u672a\u6709\u8fc7&#8221;\u75db\u98ce vs \u65e0\u75c7\u72b6\u9ad8\u5c3f\u9178\u8840\u75c7&#8221;\u7684\u5168\u57fa\u56e0\u7ec4\u6bd4\u8f83\u3002\u672c\u7814\u7a76\u586b\u8865\u4e86\u8fd9\u4e00\u7a7a\u767d\u3002<\/p>\n\n<h3>\u4e8c\u3001\u7814\u7a76\u8bbe\u8ba1\uff1a\u4e24\u9636\u6bb5\u961f\u5217\uff0c\u6570\u636e\u8d28\u91cf&#8221;\u6559\u79d1\u4e66\u7ea7&#8221;<\/h3>\n<p>\u7814\u7a76\u91c7\u7528\u4e24\u9636\u6bb5\u75c5\u4f8b\u5bf9\u7167\uff1a\u53d1\u73b0\u9636\u6bb5\uff08n=83\uff09\u7528\u5168\u57fa\u56e0\u7ec4\u9776\u5411\u91cd\u4e9a\u786b\u9178\u76d0\u6d4b\u5e8f\uff08TBS\uff09\uff0c\u9a8c\u8bc1\u9636\u6bb5\uff08n=286\uff09\u7528\u9776\u5411\u6269\u589e\u5b50\u7532\u57fa\u5316\u6d4b\u5e8f\u72ec\u7acb\u9a8c\u8bc1\u3002\u6570\u636e\u6307\u6807\u4eae\u773c\uff1a\u5355\u6837\u672c\u5e73\u5747 11.7 Gb \u6570\u636e\u91cf\u300194.8% \u6bd4\u5bf9\u7387\u300198.2% \u76ee\u6807\u8986\u76d6\u3001467 \u4e07 CpG \u4f4d\u70b9\u300154\u00d7 \u6df1\u5ea6\u3001\u8f6c\u5316\u7387 &gt;99%\u3002\u4e09\u5927\u4e24\u4e24\u6bd4\u8f83\u5206\u522b\u9501\u5b9a 289 \/ 254 \/ 291 \u4e2a\u5dee\u5f02\u7532\u57fa\u5316\u533a\u57df\uff08DMR\uff09\u3002<\/p>\n\n<figure class=\"gout-fig\">\n<img decoding=\"async\" src=\"http:\/\/afire-gene.com\/wp-content\/uploads\/2026\/11\/gout-fig1-20261117150652.webp\" alt=\"\u56fe1 \u53d1\u73b0\u961f\u5217\u7532\u57fa\u5316\u7279\u5f81\u5168\u666f\">\n<figcaption>\u56fe 1\uff5c\u53d1\u73b0\u961f\u5217\u7532\u57fa\u5316\u7279\u5f81\u5168\u666f\u3002A \u4e09\u5927\u4e24\u4e24\u6bd4\u8f83\u7684 DMR \/ DMC \u6570\u91cf\uff1a\u75db\u98ce vs \u5bf9\u7167 289 \u4e2a DMR\uff08\u9ad8\u7532\u57fa\u5316 142\u3001\u4f4e\u7532\u57fa\u5316 147\uff09\uff0c\u75db\u98ce vs \u9ad8\u5c3f\u9178 254 \u4e2a\uff0c\u9ad8\u5c3f\u9178 vs \u5bf9\u7167 291 \u4e2a\uff1b\u5355\u78b1\u57fa\u5c42\u9762\u66f4\u8fbe 7648 \/ 8296 \/ 5480 \u4e2a DMC\u3002B PCA \u4e3b\u6210\u5206\u5206\u6790\uff1a\u4e09\u7ec4\u5728\u7532\u57fa\u5316\u7a7a\u95f4\u4e2d\u6e05\u6670\u5206\u79bb\uff0c\u75db\u98ce\u4e0e\u9ad8\u5c3f\u9178\u76f8\u4e92\u9760\u8fd1\u3001\u4e0e\u6b63\u5e38\u5bf9\u7167\u660e\u663e\u5206\u5f00\uff0c\u5448\u73b0&#8221;\u6b63\u5e38 \u2192 \u9ad8\u5c3f\u9178 \u2192 \u75db\u98ce&#8221;\u7684\u68af\u5ea6\u63a8\u79fb\u3002C \u5dee\u5f02\u4f4d\u70b9\u96c6\u4e2d\u5206\u5e03\u4e8e\u57fa\u56e0\u4f53\uff0865.7%\uff09\u4e0e CpG \u5c9b \/ \u5cb8\u533a\u57df\u3002<\/figcaption>\n<\/figure>\n<p class=\"gout-quote\">\u4e00\u53e5\u8bdd\u89e3\u8bfb\uff1a\u75be\u75c5\u76f8\u5173\u7684\u7532\u57fa\u5316\u6539\u53d8\u662f\u5c40\u90e8\u3001\u6709\u5e8f\u3001\u5206\u9636\u6bb5\u7684\uff0c\u800c\u975e\u5168\u57fa\u56e0\u7ec4\u968f\u673a\u566a\u58f0\u2014\u2014\u8fd9\u6b63\u662f\u7532\u57fa\u5316\u80fd\u5f53&#8221;\u5206\u5b50\u5206\u5c42\u6807\u5c3a&#8221;\u7684\u5e95\u6c14\u3002<\/p>\n\n<h3>\u4e09\u3001\u53d1\u73b0\u4e00\uff1a\u7532\u57fa\u5316\u4e0e\u9057\u4f20\u98ce\u9669&#8221;\u6b8a\u9014\u540c\u5f52&#8221;<\/h3>\n<p>\u5c06 541 \u4e2a\u5dee\u5f02\u7532\u57fa\u5316\u57fa\u56e0\u4e0e 2703 \u4e2a\u75db\u98ce \/ \u5c3f\u9178 GWAS \u4f4d\u70b9\u4ea4\u53c9\uff0c\u5f97\u5230 84 \u4e2a\u540c\u65f6\u643a\u5e26\u9057\u4f20\u53d8\u5f02\u4e0e\u7532\u57fa\u5316\u6539\u53d8\u7684\u57fa\u56e0\u3002\u901a\u8def\u5bcc\u96c6\u9ad8\u5ea6\u96c6\u4e2d\u4e8e\u6297\u539f\u52a0\u5de5\u4e0e\u5448\u9012\uff0c\u5e76\u5ef6\u4f38\u81f3\u514d\u75ab\u4ecb\u5bfc\u75be\u75c5\u4e0e\u4ee3\u8c22\u8f74\uff1b\u7f51\u7edc\u4e2d HLA-DRB1\u3001TAP2\u3001GNAS \u8fde\u63a5\u5ea6\u6700\u9ad8\uff0c\u628a\u514d\u75ab\u6fc0\u6d3b\u4e0e\u4ee3\u8c22\u7d0a\u4e71\u4e24\u6761\u4e3b\u7ebf\u7d22\u4e32\u5728\u4e00\u8d77\u3002<\/p>\n\n<figure class=\"gout-fig\">\n<img decoding=\"async\" src=\"http:\/\/afire-gene.com\/wp-content\/uploads\/2026\/11\/gout-fig2-20261117150652.webp\" alt=\"\u56fe2 \u7532\u57fa\u5316\u4fe1\u53f7\u4e0e GWAS \u98ce\u9669\u4f4d\u70b9\u7684\u4ea4\u6c47\">\n<figcaption>\u56fe 2\uff5c\u7532\u57fa\u5316\u4fe1\u53f7\u4e0e GWAS \u98ce\u9669\u4f4d\u70b9\u7684\u4ea4\u6c47\u3002A \u97e6\u6069\u56fe\uff1a2619 \u4e2a GWAS \u98ce\u9669\u57fa\u56e0\u4e0e 457 \u4e2a\u5dee\u5f02\u7532\u57fa\u5316\u57fa\u56e0\u4ea4\u6c47\u51fa 84 \u4e2a&#8221;\u9057\u4f20 + \u8868\u89c2&#8221;\u53cc\u91cd\u8bc1\u636e\u57fa\u56e0\u3002B KEGG \u5bcc\u96c6\uff1a\u6297\u539f\u52a0\u5de5\u4e0e\u5448\u9012\u901a\u8def\u663e\u8457\u6027\u6700\u9ad8\uff0c\u5e76\u5ef6\u4f38\u81f3\u514d\u75ab\u4ecb\u5bfc\u75be\u75c5\u4e0e\u75c5\u6bd2\u611f\u67d3\u901a\u8def\u3002C \u57fa\u56e0-\u901a\u8def\u7f51\u7edc\uff1aHLA-DRB1\u3001TAP2\u3001GNAS \u7b49\u67a2\u7ebd\u8282\u70b9\u8fde\u63a5\u591a\u6761\u514d\u75ab\u4e0e\u5185\u5206\u6ccc\u901a\u8def\u3002<\/figcaption>\n<\/figure>\n<p class=\"gout-quote\">\u4e00\u53e5\u8bdd\u89e3\u8bfb\uff1a\u9057\u4f20\u98ce\u9669\u4e0d\u662f&#8221;\u4e00\u952e\u53d1\u75c5&#8221;\uff0c\u800c\u662f\u8981\u7ecf\u8fc7\u7532\u57fa\u5316\u8fd9\u5c42\u8c03\u5149\u5f00\u5173\u7684\u653e\u5927\u6216\u6291\u5236\u2014\u2014\u7532\u57fa\u5316\u6b63\u662f\u51b3\u5b9a\u9057\u4f20\u6613\u611f\u6027\u662f\u5426\u88ab\u7ffb\u8bd1\u6210\u75be\u75c5\u7684\u5173\u952e\u8c03\u63a7\u5c42\u3002<\/p>\n\n<h3>\u56db\u3001\u53d1\u73b0\u4e8c\uff1a\u8f6c\u5f55\u56e0\u5b50\u8c03\u63a7\u7f51\u7edc\u6d6e\u51fa\u6c34\u9762<\/h3>\n<p>\u7814\u7a76\u5728 1172 \u4e2a\u8f6c\u5f55\u56e0\u5b50\u7684 360 \u4e07\u4e2a\u7ed3\u5408\u4f4d\u70b9\u4e2d\u7b5b\u51fa 16 \u4e2a\u663e\u8457\u5bcc\u96c6\u56e0\u5b50\uff0c\u5176\u4e2d MLXIPL\u3001ZSCAN5A\u3001ZBTB45\u3001ZNF571 \u6700\u5f3a\u3002\u7f51\u7edc\u663e\u793a ZNF571 \u662f\u75db\u98ce\u7279\u5f02\u6027\u9ad8\u7532\u57fa\u5316\u7684\u5019\u9009\u4e0a\u6e38\u56e0\u5b50\uff0c\u9884\u6d4b\u9776\u70b9\u5305\u62ec\u708e\u75c7\u5173\u952e\u4ecb\u8d28 IL27 \u4e0e SAA2\uff0c\u4e3a\u9ad8\u5c3f\u9178\u5411\u75db\u98ce\u8f6c\u53d8\u4e2d\u7684\u514d\u75ab\u542f\u52a8\u673a\u5236\u63d0\u4f9b\u4e86\u65b0\u5047\u8bbe\u3002<\/p>\n\n<figure class=\"gout-fig\">\n<img decoding=\"async\" src=\"http:\/\/afire-gene.com\/wp-content\/uploads\/2026\/11\/gout-fig3-20261117150652.webp\" alt=\"\u56fe3 \u8f6c\u5f55\u56e0\u5b50\u7ed3\u5408\u4f4d\u70b9\u5bcc\u96c6\u4e0e\u8c03\u63a7\u7f51\u7edc\">\n<figcaption>\u56fe 3\uff5c\u8f6c\u5f55\u56e0\u5b50\u7ed3\u5408\u4f4d\u70b9\u5bcc\u96c6\u4e0e\u8c03\u63a7\u7f51\u7edc\u3002A \u6c14\u6ce1\u56fe\uff1a16 \u4e2a\u8f6c\u5f55\u56e0\u5b50\u7684\u7ed3\u5408\u4f4d\u70b9\u5728\u75db\u98ce\u76f8\u5173\u9ad8\u7532\u57fa\u5316\u4f4d\u70b9\u4e2d\u663e\u8457\u5bcc\u96c6\uff08\u5bcc\u96c6\u500d\u6570 &gt;2\uff0cFDR&lt;0.01\uff09\u3002B \u8c03\u63a7\u7f51\u7edc\uff1aZNF571 \u4e0e\u708e\u75c7\u4ecb\u8d28 IL27\u3001SAA2 \u7b49\u9884\u6d4b\u9776\u57fa\u56e0\u76f8\u8fde\u3002C \u56db\u4e2a Top \u8f6c\u5f55\u56e0\u5b50\uff08MLXIPL \/ ZSCAN5A \/ ZBTB45 \/ ZNF571\uff09\u7684\u7ed3\u5408 motif \u4e0e\u5bcc\u96c6\u66f2\u7ebf\u3002<\/figcaption>\n<\/figure>\n<p class=\"gout-quote\">\u4e00\u53e5\u8bdd\u89e3\u8bfb\uff1a\u8fd9\u63d0\u793a\u75db\u98ce\u53ef\u80fd\u5b58\u5728&#8221;\u8bad\u7ec3\u514d\u75ab&#8221;\u5f0f\u7684\u56fa\u6709\u514d\u75ab\u9884\u6fc0\u2014\u2014\u5728\u53d1\u75c5\u4e4b\u524d\uff0c\u7532\u57fa\u5316\u5c31\u5df2\u7ecf\u628a\u708e\u75c7\u7684\u5f15\u4fe1\u88c5\u597d\u4e86\u3002<\/p>\n\n<h3>\u4e94\u3001\u53d1\u73b0\u4e09\uff1a\u7532\u57fa\u5316\u8bca\u65ad\u6a21\u578b\u5168\u9762&#8221;\u7834\u5708&#8221;<\/h3>\n<p>\u9a8c\u8bc1\u9636\u6bb5\u786e\u8ba4 113 \u4e2a\u5dee\u5f02\u7532\u57fa\u5316\u4f4d\u70b9\uff0c\u7ecf BMI\u3001\u8840\u7cd6\u3001\u808c\u9150\u6821\u6b63\u540e\u4fdd\u7559 90 \u4e2a\uff0c\u7528 LASSO \u903b\u8f91\u56de\u5f52\u6784\u5efa&#8221;\u4ec5\u7532\u57fa\u5316 \/ \u4ec5\u4e34\u5e8a \/ \u8054\u5408&#8221;\u4e09\u7c7b\u6a21\u578b\uff0c\u72ec\u7acb\u6d4b\u8bd5\u96c6\u6210\u7ee9\u5982\u4e0b\uff1a<\/p>\n\n<table class=\"gout-table\">\n<tbody>\n<tr><th>\u5bf9\u6bd4\u573a\u666f<\/th><th>\u4ec5\u4e34\u5e8a AUC<\/th><th>\u4ec5\u7532\u57fa\u5316 AUC<\/th><th>\u8054\u5408\u6a21\u578b AUC<\/th><\/tr>\n<tr><td>\u75db\u98ce vs \u975e\u75db\u98ce<\/td><td>0.78<\/td><td>0.91<\/td><td>0.83<\/td><\/tr>\n<tr><td>\u75db\u98ce vs \u65e0\u75c7\u72b6\u9ad8\u5c3f\u9178<\/td><td>0.67<\/td><td>0.80<\/td><td>0.87<\/td><\/tr>\n<tr><td>\u5c3f\u9178\u4ee3\u8c22\u5f02\u5e38 vs \u6b63\u5e38<\/td><td>0.88<\/td><td>0.82<\/td><td>0.94<\/td><\/tr>\n<tr><td>\u75db\u98ce vs \u6b63\u5e38\u5bf9\u7167<\/td><td>0.87<\/td><td>0.96<\/td><td>0.92<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<figure class=\"gout-fig\">\n<img decoding=\"async\" src=\"http:\/\/afire-gene.com\/wp-content\/uploads\/2026\/11\/gout-fig4-20261117150652.webp\" alt=\"\u56fe4 \u56db\u7c7b\u8bca\u65ad\u573a\u666f\u7684 ROC \u66f2\u7ebf\u5bf9\u6bd4\">\n<figcaption>\u56fe 4\uff5c\u56db\u7c7b\u8bca\u65ad\u573a\u666f\u7684 ROC \u66f2\u7ebf\u5bf9\u6bd4\u3002A \u75db\u98ce vs \u975e\u75db\u98ce\uff1a\u4ec5\u7532\u57fa\u5316 AUC 0.913\uff0c\u663e\u8457\u9ad8\u4e8e\u4ec5\u4e34\u5e8a 0.78\uff08DeLong P=0.032\uff09\uff1bB \u75db\u98ce vs \u65e0\u75c7\u72b6\u9ad8\u5c3f\u9178\uff1a\u8054\u5408\u6a21\u578b 0.871\uff0c\u663e\u8457\u9ad8\u4e8e\u4ec5\u4e34\u5e8a 0.673\uff08P=0.018\uff09\uff1bC \u5c3f\u9178\u4ee3\u8c22\u5f02\u5e38 vs \u6b63\u5e38\uff1a\u8054\u5408\u6a21\u578b 0.937\uff1bD \u75db\u98ce vs \u6b63\u5e38\u5bf9\u7167\uff1a\u4ec5\u7532\u57fa\u5316 0.959\uff0c\u4e3a\u5168\u7814\u7a76\u6700\u9ad8\u3002\u66f2\u7ebf\u8d8a\u8d34\u8fd1\u5de6\u4e0a\u89d2\uff0c\u533a\u5206\u5ea6\u8d8a\u9ad8\u3002<\/figcaption>\n<\/figure>\n\n<p>\u4e09\u70b9\u503c\u5f97\u5173\u6ce8\uff1a\u75db\u98ce vs \u6b63\u5e38\u5bf9\u7167\u4ec5\u7532\u57fa\u5316\u6a21\u578b AUC \u8fbe 0.96\uff0c\u4e3a\u5168\u7814\u7a76\u6700\u9ad8\uff1b\u75db\u98ce vs \u975e\u75db\u98ce\uff0c\u7532\u57fa\u5316\u663e\u8457\u4f18\u4e8e\u4e34\u5e8a\u6307\u6807\uff080.91 vs 0.78\uff0cP=0.032\uff09\uff1b\u800c\u4e34\u5e8a\u51e0\u4e4e\u65e0\u89e3\u7684\u75db\u98ce vs \u65e0\u75c7\u72b6\u9ad8\u5c3f\u9178\uff0c\u8054\u5408\u6a21\u578b\u628a AUC \u4ece 0.67 \u62c9\u5230 0.87\uff08P=0.018\uff09\uff0c\u8bc1\u660e\u7532\u57fa\u5316\u643a\u5e26\u4e86\u72ec\u7acb\u4e8e\u8840\u5c3f\u9178\u7684\u8bca\u65ad\u4fe1\u606f\u3002<\/p>\n\n<h3>\u516d\u3001\u884c\u4e1a\u610f\u4e49\uff1a\u4ece&#8221;\u770b\u5c3f\u9178&#8221;\u5230&#8221;\u770b\u8868\u89c2\u57fa\u56e0\u7ec4&#8221;<\/h3>\n<p>\u8fd9\u9879\u7814\u7a76\u628a\u75db\u98ce\u5206\u5b50\u5206\u5c42\u7684\u8fb9\u754c\uff0c\u4ece\u5355\u4e00\u8840\u5c3f\u9178\u63a8\u8fdb\u5230\u8868\u89c2\u57fa\u56e0\u7ec4\u5c42\u9762\uff1a\u8bca\u65ad\u7aef\uff0c\u7532\u57fa\u5316\u6807\u5fd7\u7269\u6709\u671b\u8865\u8db3\u8840\u5c3f\u9178\u77ed\u677f\uff0c\u5c24\u5176\u5728\u68d8\u624b\u5206\u578b\u4e2d\u63d0\u4f9b\u51b3\u7b56\u4f9d\u636e\uff1b\u7814\u53d1\u7aef\uff0c\u836f\u7269\u91cd\u5b9a\u4f4d\u5206\u6790\u6307\u5411\u5fc3\u8840\u7ba1\u3001\u547c\u5438\u4e0e\u6ccc\u5c3f\u7cfb\u7edf\u9776\u70b9\uff0c\u4e3a\u5171\u75c5\u673a\u5236\u4e0e\u65b0\u836f\u65b9\u5411\u63d0\u4f9b\u7ebf\u7d22\uff1b\u670d\u52a1\u7aef\uff0c\u672c\u9879\u76ee\u9a8c\u8bc1\u4e86\u5927\u89c4\u6a21\u3001\u9ad8\u6df1\u5ea6\u7532\u57fa\u5316\u6d4b\u5e8f\u5728\u590d\u6742\u6162\u75c5\u961f\u5217\u4e2d\u7684\u7a33\u5b9a\u4ea4\u4ed8\u80fd\u529b\u3002<\/p>\n<p class=\"gout-note\">\u5ba1\u614e\u8bf4\u660e\uff1a\u672c\u7814\u7a76\u961f\u5217\u4e3a\u7537\u6027\u3001\u5e74\u9f84\u533a\u95f4\u8f83\u7a84\u4e14\u5747\u4e3a\u521d\u8bca\u672a\u6cbb\u7597\u4eba\u7fa4\uff0c\u7532\u57fa\u5316\u6807\u5fd7\u7269\u8fdb\u5165\u4e34\u5e8a\u524d\u4ecd\u9700\u524d\u77bb\u6027\u9a8c\u8bc1\u3002<\/p>\n\n<h3>\u7ed3\u8bed<\/h3>\n<p>\u4ece 369 \u4f8b\u6837\u672c\u5230 AUC 0.96\uff0c\u4ece 84 \u4e2a\u9057\u4f20-\u8868\u89c2\u4ea4\u6c47\u57fa\u56e0\u5230 ZNF571 \u8c03\u63a7\u7f51\u7edc\uff0c\u8fd9\u7bc7 IF 24 \u4e00\u533a\u8bba\u6587\u4e0d\u53ea\u662f\u4e00\u6b21&#8221;\u53d1\u8868&#8221;\uff0c\u66f4\u662f\u75db\u98ce\u8868\u89c2\u57fa\u56e0\u7ec4\u5b66\u4ece 0 \u5230 1 \u7684\u5206\u5c42\u8303\u5f0f\u786e\u7acb\u3002\u4f5c\u4e3a\u672c\u7814\u7a76\u7684\u7532\u57fa\u5316\u6d4b\u5e8f\u4e0e\u8868\u89c2\u5206\u6790\u670d\u52a1\u65b9\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u4ee5\u9ad8\u6df1\u5ea6\u3001\u9ad8\u8986\u76d6\u3001\u53ef\u91cd\u590d\u7684\u6280\u672f\u4f53\u7cfb\uff0c\u4e0e\u66f4\u591a\u4e34\u5e8a\u4e0e\u79d1\u7814\u56e2\u961f\u4e00\u8d77\uff0c\u628a\u8868\u89c2\u9057\u4f20\u5b66\u53d1\u73b0\u63a8\u5411\u771f\u6b63\u7684\u4e34\u5e8a\u4ef7\u503c\u3002<\/p>\n\n<h3>\u9644\u5f55\uff1a\u6280\u672f\u670d\u52a1\u54a8\u8be2<\/h3>\n<p>\u7532\u57fa\u5316\u6d4b\u5e8f \/ \u8868\u89c2\u57fa\u56e0\u7ec4\u5b66\u6d4b\u5e8f\u670d\u52a1\uff08\u9776\u5411\u91cd\u4e9a\u786b\u9178\u76d0\u6d4b\u5e8f TBS\u3001\u9776\u5411\u6269\u589e\u5b50\u7532\u57fa\u5316\u6d4b\u5e8f\u3001\u5168\u57fa\u56e0\u7ec4\u7532\u57fa\u5316\u56fe\u8c31\u4e0e\u8bca\u65ad\u6a21\u578b\u6784\u5efa\uff09\uff0c\u6b22\u8fce\u8054\u7cfb\u6211\u4eec\u3002<\/p>\n<p class=\"gout-contact\">\u5ba2\u6237\u670d\u52a1\u90e8\uff1a19925189446\u3000\u5ba2\u670d\u90ae\u7bb1\uff1a<a href=\"mailto:service@afire-gene.com\">service@afire-gene.com<\/a><\/p>\n<\/div>\n\n<div class=\"gout-en\">\n<p class=\"gout-kicker\">Methylation Sequencing \u00b7 Epigenomics Services \u00b7 Research Highlight<\/p>\n<h2 class=\"gout-h1\">The Largest Gout DNA Methylation Study in China to Date<\/h2>\n<p class=\"gout-sub\">Published in <strong>Annals of the Rheumatic Diseases<\/strong> (2026) \u00b7 IF 24 \u00b7 CAS Zone 1<\/p>\n\n<div class=\"gout-stats\">\n  <div class=\"gout-stat\"><span class=\"gout-num\">369<\/span><span class=\"gout-label\">Samples in the methylation cohort<\/span><\/div>\n  <div class=\"gout-stat\"><span class=\"gout-num\">0.96<\/span><span class=\"gout-label\">Highest AUC of the methylation model<\/span><\/div>\n  <div class=\"gout-stat\"><span class=\"gout-num\">84<\/span><span class=\"gout-label\">Genes with combined genetic and epigenetic evidence<\/span><\/div>\n<\/div>\n\n<h3>Executive summary<\/h3>\n<table class=\"gout-table\">\n<tbody>\n<tr><th>Journal<\/th><th>Methylation cohort<\/th><th>Highest diagnostic AUC<\/th><\/tr>\n<tr><td>IF 24 \u00b7 CAS Zone 1<br>Ann Rheum Dis (leading rheumatology journal)<\/td><td>369 participants<br>gout 124 \/ asymptomatic hyperuricemia 121 \/ healthy controls 124<\/td><td>0.96<br>gout vs healthy controls (methylation model alone)<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<p>A landmark study in gout epigenomics has been published in <em>Annals of the Rheumatic Diseases<\/em> (Ann Rheum Dis; impact factor 24; CAS Zone 1), a leading journal in rheumatology. The work was conducted jointly by teams from the Affiliated Hospital of Qingdao University, Huashan Hospital of Fudan University, South China University of Technology and the Kennedy Institute of Rheumatology, University of Oxford. AfireGene provided the full workflow of DNA methylation sequencing and epigenomic analysis.<\/p>\n<p>Based on 369 participants, the study established the largest publicly reported DNA methylation cohort of gout and hyperuricemia to date, and for the first time constructed and validated a high-performance methylation-based diagnostic model. The AUC reached 0.96 for gout versus healthy controls, and increased from 0.67 to 0.87 for the most difficult clinical discrimination \u2014 gout versus asymptomatic hyperuricemia (AHU). This is more than a methodological advance: the gap between &#8220;elevated serum uric acid (SUA)&#8221; and &#8220;established gout&#8221; has, for the first time, received a molecular annotation at the methylation level.<\/p>\n\n<h3>1. Background: why elevated SUA does not equal gout<\/h3>\n<p>Gout results from monosodium urate (MSU) crystal deposition during long-standing hyperuricemia. However, elevated SUA is only a necessary condition \u2014 the great majority of individuals with hyperuricemia never develop the disease. Susceptibility variants identified by previous genome-wide association studies (GWAS) lie mostly in non-coding regions and explain only a small fraction of the genetic risk. DNA methylation is a key epigenetic switch linking genetic background to environmental exposure, yet earlier studies were restricted to a few candidate genes, and a genome-wide comparison of gout versus AHU had never been performed. This study fills that gap.<\/p>\n\n<h3>2. Study design: a two-stage cohort with textbook-quality data<\/h3>\n<p>A two-stage case\u2013control design was used. The discovery stage (n=83) applied genome-wide targeted bisulfite sequencing (TBS), and the validation stage (n=286) independently verified the findings using targeted amplicon methylation sequencing. The data metrics were strong: a mean of 11.7 Gb per sample, an alignment rate of 94.8%, on-target coverage of 98.2%, 4.67 million CpG sites, a mean depth of 54\u00d7 and a bisulfite conversion rate above 99%. The three pairwise comparisons identified 289, 254 and 291 differentially methylated regions (DMRs), respectively.<\/p>\n\n<figure class=\"gout-fig\">\n<img decoding=\"async\" src=\"http:\/\/afire-gene.com\/wp-content\/uploads\/2026\/11\/gout-fig1-20261117150652.webp\" alt=\"Figure 1 Landscape of methylation features in the discovery cohort\">\n<figcaption>Figure 1 | Landscape of methylation features in the discovery cohort. (A) Numbers of DMRs and differentially methylated CpG sites (DMCs) across the three pairwise comparisons: gout vs control, 289 DMRs (142 hypermethylated, 147 hypomethylated); gout vs hyperuricemia, 254; hyperuricemia vs control, 291; at single-base resolution, 7,648 \/ 8,296 \/ 5,480 DMCs. (B) Principal component analysis (PCA): the three groups separate clearly in methylation space, with gout and hyperuricemia close to each other and both distant from healthy controls, showing a &#8220;normal \u2192 hyperuricemia \u2192 gout&#8221; gradient. (C) Differentially methylated sites concentrate in gene bodies (65.7%) and CpG island\/shore regions.<\/figcaption>\n<\/figure>\n<p class=\"gout-quote\">In brief: disease-associated methylation changes are focal, ordered and stage-dependent rather than genome-wide random noise \u2014 precisely why methylation can serve as a molecular stratification ruler.<\/p>\n\n<h3>3. Finding 1: methylation and genetic risk converge on the same pathways<\/h3>\n<p>Cross-referencing 541 differentially methylated genes with 2,703 gout and uric acid GWAS loci identified 84 genes carrying both genetic variants and methylation changes. Pathway enrichment was concentrated in antigen processing and presentation and extended to immune-mediated diseases and metabolic axes. HLA-DRB1, TAP2 and GNAS showed the highest connectivity in the network, linking immune activation with metabolic dysregulation.<\/p>\n\n<figure class=\"gout-fig\">\n<img decoding=\"async\" src=\"http:\/\/afire-gene.com\/wp-content\/uploads\/2026\/11\/gout-fig2-20261117150652.webp\" alt=\"Figure 2 Convergence of methylation signals and GWAS risk loci\">\n<figcaption>Figure 2 | Convergence of methylation signals and GWAS risk loci. (A) Venn diagram: 2,619 GWAS risk genes and 457 differentially methylated genes overlap in 84 genes with dual genetic and epigenetic evidence. (B) KEGG enrichment: antigen processing and presentation is the most significant pathway, extending to immune-mediated disease and viral infection pathways. (C) Gene\u2013pathway network: hub genes such as HLA-DRB1, TAP2 and GNAS connect multiple immune and endocrine pathways.<\/figcaption>\n<\/figure>\n<p class=\"gout-quote\">In brief: genetic risk is not a single-step trigger; it passes through the methylation dimmer, which amplifies or suppresses it. Methylation is the regulatory layer that determines whether genetic susceptibility is translated into disease.<\/p>\n\n<h3>4. Finding 2: a transcription factor regulatory network emerges<\/h3>\n<p>Among 3.6 million binding sites of 1,172 transcription factors (TFs), 16 significantly enriched TFs were identified, with MLXIPL, ZSCAN5A, ZBTB45 and ZNF571 being the strongest. The network suggests ZNF571 as a candidate upstream regulator of gout-specific hypermethylation, with predicted targets including the key inflammatory mediators IL-27 and SAA2, providing a new hypothesis for immune priming during the transition from hyperuricemia to gout.<\/p>\n\n<figure class=\"gout-fig\">\n<img decoding=\"async\" src=\"http:\/\/afire-gene.com\/wp-content\/uploads\/2026\/11\/gout-fig3-20261117150652.webp\" alt=\"Figure 3 Enrichment of transcription factor binding sites and the regulatory network\">\n<figcaption>Figure 3 | Enrichment of transcription factor binding sites and the regulatory network. (A) Bubble plot: binding sites of 16 TFs are significantly enriched among gout-associated hypermethylated sites (fold enrichment &gt;2, FDR&lt;0.01). (B) Regulatory network: ZNF571 is linked to predicted target genes including the inflammatory mediators IL-27 and SAA2. (C) Binding motifs and enrichment curves of the top four TFs (MLXIPL, ZSCAN5A, ZBTB45 and ZNF571).<\/figcaption>\n<\/figure>\n<p class=\"gout-quote\">In brief: this points to a trained-immunity-like innate immune priming in gout \u2014 methylation has already set the inflammatory fuse before clinical onset.<\/p>\n\n<h3>5. Finding 3: the methylation-based diagnostic model performs across scenarios<\/h3>\n<p>The validation stage confirmed 113 differentially methylated sites, of which 90 were retained after adjustment for body mass index (BMI), blood glucose and creatinine. LASSO logistic regression was used to build methylation-only, clinical-only and combined models, with the following results on the independent test set:<\/p>\n\n<table class=\"gout-table\">\n<tbody>\n<tr><th>Comparison<\/th><th>Clinical model AUC<\/th><th>Methylation-only AUC<\/th><th>Combined model AUC<\/th><\/tr>\n<tr><td>Gout vs non-gout<\/td><td>0.78<\/td><td>0.91<\/td><td>0.83<\/td><\/tr>\n<tr><td>Gout vs AHU<\/td><td>0.67<\/td><td>0.80<\/td><td>0.87<\/td><\/tr>\n<tr><td>Abnormal urate metabolism vs normal<\/td><td>0.88<\/td><td>0.82<\/td><td>0.94<\/td><\/tr>\n<tr><td>Gout vs healthy controls<\/td><td>0.87<\/td><td>0.96<\/td><td>0.92<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<figure class=\"gout-fig\">\n<img decoding=\"async\" src=\"http:\/\/afire-gene.com\/wp-content\/uploads\/2026\/11\/gout-fig4-20261117150652.webp\" alt=\"Figure 4 ROC curves across four diagnostic scenarios\">\n<figcaption>Figure 4 | Receiver operating characteristic (ROC) curves across the four diagnostic scenarios. (A) Gout vs non-gout: methylation-only AUC 0.913, significantly higher than the clinical model (0.78; DeLong test P=0.032). (B) Gout vs AHU: combined model AUC 0.871, significantly higher than the clinical model (0.673; P=0.018). (C) Abnormal urate metabolism vs normal: combined model 0.937. (D) Gout vs healthy controls: methylation-only 0.959, the highest in the study.<\/figcaption>\n<\/figure>\n\n<p>Three findings deserve attention. First, the methylation-only model reached an AUC of 0.96 for gout versus healthy controls, the highest in the study. Second, for gout versus non-gout, methylation significantly outperformed conventional clinical indicators (0.91 vs 0.78; P=0.032). Third, for gout versus AHU \u2014 a discrimination that clinical variables alone can hardly resolve \u2014 the combined model raised the AUC from 0.67 to 0.87 (P=0.018), demonstrating that methylation carries diagnostic information independent of SUA.<\/p>\n\n<h3>6. Significance: from measuring uric acid to reading the epigenome<\/h3>\n<p>The study extends the boundary of molecular stratification in gout from a single SUA measurement to the epigenome. On the diagnostic side, methylation markers may compensate for the limitations of SUA and support decision-making in difficult subtypes. On the research and development side, drug repositioning analysis points to cardiovascular, respiratory and urological targets, offering clues for comorbidity mechanisms and new therapeutic directions. On the service side, the project demonstrates reliable delivery of large-scale, high-depth methylation sequencing in complex chronic-disease cohorts.<\/p>\n<p class=\"gout-note\">Caveat: the cohort consisted of men only, with a narrow age range, all newly diagnosed and untreated. Prospective validation is still required before methylation markers can enter clinical practice.<\/p>\n\n<h3>Conclusion<\/h3>\n<p>From 369 samples to an AUC of 0.96, from 84 genes with combined genetic and epigenetic evidence to the ZNF571 regulatory network, this IF 24, CAS Zone 1 paper is more than a publication \u2014 it establishes a stratification paradigm for gout epigenomics. As the provider of methylation sequencing and epigenomic analysis for this study, AfireGene will continue to work with clinical and research teams, applying deep, comprehensive and reproducible technical systems to translate epigenetic discoveries into clinical value.<\/p>\n\n<h3>Appendix: Technical service enquiries<\/h3>\n<p>Methylation sequencing and epigenomics services \u2014 targeted bisulfite sequencing (TBS), targeted amplicon methylation sequencing, genome-wide methylation profiling and diagnostic model construction. We welcome your enquiries.<\/p>\n<p class=\"gout-contact\">Customer Service: +86 199 2518 9446\u3000Email: <a href=\"mailto:service@afire-gene.com\">service@afire-gene.com<\/a><\/p>\n<\/div>\n\n<\/div>","protected":false},"excerpt":{"rendered":"<p>\u7532\u57fa\u5316\u6d4b\u5e8f \u00b7 \u8868\u89c2\u57fa\u56e0\u7ec4\u5b66\u670d\u52a1 \u00b7 \u6210 [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-1834","page","type-page","status-publish","hentry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"chenshengding","author_link":"https:\/\/afire-gene.com\/en\/author\/chenshengding\/"},"uagb_comment_info":0,"uagb_excerpt":"\u7532\u57fa\u5316\u6d4b\u5e8f \u00b7 \u8868\u89c2\u57fa\u56e0\u7ec4\u5b66\u670d\u52a1 \u00b7 \u6210 [&hellip;]","_links":{"self":[{"href":"https:\/\/afire-gene.com\/en\/wp-json\/wp\/v2\/pages\/1834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/afire-gene.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/afire-gene.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/afire-gene.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/afire-gene.com\/en\/wp-json\/wp\/v2\/comments?post=1834"}],"version-history":[{"count":0,"href":"https:\/\/afire-gene.com\/en\/wp-json\/wp\/v2\/pages\/1834\/revisions"}],"wp:attachment":[{"href":"https:\/\/afire-gene.com\/en\/wp-json\/wp\/v2\/media?parent=1834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}